TWI708604B - 用於治療皮膚疾病及病狀之包含7-(1h-咪唑-4-基甲基)-5,6,7,8-四氫-喹啉之醫藥組合物 - Google Patents

用於治療皮膚疾病及病狀之包含7-(1h-咪唑-4-基甲基)-5,6,7,8-四氫-喹啉之醫藥組合物 Download PDF

Info

Publication number
TWI708604B
TWI708604B TW106103338A TW106103338A TWI708604B TW I708604 B TWI708604 B TW I708604B TW 106103338 A TW106103338 A TW 106103338A TW 106103338 A TW106103338 A TW 106103338A TW I708604 B TWI708604 B TW I708604B
Authority
TW
Taiwan
Prior art keywords
skin
imidazol
tetrahydro
quinoline
ylmethyl
Prior art date
Application number
TW106103338A
Other languages
English (en)
Chinese (zh)
Other versions
TW201713338A (zh
Inventor
I 迪巴斯墨漢美德
C 夏愛德華
E 東尼歐約翰
W 吉爾丹尼爾
Original Assignee
美商歐樂根公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47178364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI708604(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 美商歐樂根公司 filed Critical 美商歐樂根公司
Publication of TW201713338A publication Critical patent/TW201713338A/zh
Application granted granted Critical
Publication of TWI708604B publication Critical patent/TWI708604B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
TW106103338A 2011-11-10 2012-11-09 用於治療皮膚疾病及病狀之包含7-(1h-咪唑-4-基甲基)-5,6,7,8-四氫-喹啉之醫藥組合物 TWI708604B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161558104P 2011-11-10 2011-11-10
US61/558,104 2011-11-10

Publications (2)

Publication Number Publication Date
TW201713338A TW201713338A (zh) 2017-04-16
TWI708604B true TWI708604B (zh) 2020-11-01

Family

ID=47178364

Family Applications (3)

Application Number Title Priority Date Filing Date
TW106103338A TWI708604B (zh) 2011-11-10 2012-11-09 用於治療皮膚疾病及病狀之包含7-(1h-咪唑-4-基甲基)-5,6,7,8-四氫-喹啉之醫藥組合物
TW101141967A TWI580424B (zh) 2011-11-10 2012-11-09 用於治療皮膚疾病及病狀之包含７－（１ｈ－咪唑－４－基甲基）－５，６，７，８－四氫－喹啉之醫藥組合物
TW108123351A TW202014189A (zh) 2011-11-10 2012-11-09 用於治療皮膚疾病及病狀之包含7-(1h-咪唑-4-基甲基)-5,6,7,8-四氫-喹啉之醫藥組合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW101141967A TWI580424B (zh) 2011-11-10 2012-11-09 用於治療皮膚疾病及病狀之包含７－（１ｈ－咪唑－４－基甲基）－５，６，７，８－四氫－喹啉之醫藥組合物
TW108123351A TW202014189A (zh) 2011-11-10 2012-11-09 用於治療皮膚疾病及病狀之包含7-(1h-咪唑-4-基甲基)-5,6,7,8-四氫-喹啉之醫藥組合物

Country Status (22)

Country Link
US (4) US20130123303A1 (enExample)
EP (3) EP3184110B1 (enExample)
JP (2) JP6359456B2 (enExample)
KR (1) KR102004563B1 (enExample)
CN (1) CN104136029A (enExample)
AR (1) AR088845A1 (enExample)
AU (2) AU2012335803B2 (enExample)
BR (1) BR112014011336A2 (enExample)
CA (1) CA2855005C (enExample)
CL (1) CL2014001242A1 (enExample)
DK (1) DK2776034T3 (enExample)
ES (1) ES2635421T3 (enExample)
IL (3) IL232483B (enExample)
MX (1) MX350662B (enExample)
MY (1) MY182553A (enExample)
PH (1) PH12014501051A1 (enExample)
RU (2) RU2667645C1 (enExample)
SG (3) SG10201809506TA (enExample)
TW (3) TWI708604B (enExample)
UA (1) UA109359C2 (enExample)
WO (1) WO2013070861A1 (enExample)
ZA (1) ZA201403396B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
ES2765264T3 (es) * 2013-05-06 2020-06-08 Allergan Inc Agonistas alfa-adrenérgicos para el tratamiento de traumatismo tisular
FR3061434B1 (fr) * 2017-01-04 2019-07-12 Pierre Fabre Dermo-Cosmetique Composition cosmetique comprenant une association d'huile de pongamia et de pentylene glycol 4-t-butylcyclohexanol pour lutter contre la rosacee
RU2727695C1 (ru) * 2020-02-13 2020-07-22 Мурад Умарович Магомедов Способ комплексного лечения ринофимы

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU763164B2 (en) * 1998-05-08 2003-07-17 University Of Miami Use of tetracyclines for treating meibomian gland disease
WO2004073708A1 (en) * 1998-12-17 2004-09-02 Dean Thomas R Brinzolamide and brimonidine for treating ocular conditions
US20010049369A1 (en) * 2000-02-10 2001-12-06 Jablonski Monica M. Brimonidine compositions and methods for retinal degeneration
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US6680062B2 (en) 2001-10-05 2004-01-20 Color Access, Inc. Anti-irritating rosacea treatment
US7030149B2 (en) * 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US20040146539A1 (en) * 2003-01-24 2004-07-29 Gupta Shyam K. Topical Nutraceutical Compositions with Selective Body Slimming and Tone Firming Antiaging Benefits
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
CN100558360C (zh) * 2003-11-20 2009-11-11 奥特拉控股公司 羟胺组合物在制备缓解黄斑变性和其他眼科疾病的药物中的用途
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
MXPA06013649A (es) * 2004-05-25 2007-07-09 Sansrosa Pharmaceutical Dev In Compuestos, formulaciones, y metodos para tratar o prevenir desordenes inflamatorios de la piel.
US20070203144A1 (en) * 2006-01-17 2007-08-30 Allergan, Inc. Use of Memantine and Brimonidine to Attenuate Vitreoretinal Vascular Endothelial Growth Factor (VEGF) Protein Levels in Animals
US7323477B2 (en) 2006-02-02 2008-01-29 Allergan, Inc. 7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline
RU2321399C1 (ru) * 2006-06-01 2008-04-10 Федеральное государственное учреждение "Нижегородский научно-исследовательский кожно-венерологический институт Федерального агентства по здравоохранению и социальному развитию" Способ лечения больных розацеа
WO2008124151A2 (en) * 2007-04-09 2008-10-16 Avicena Group, Inc. Use of creatine compounds for the treatment of eye disorders
US20090061020A1 (en) * 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
WO2009052073A2 (en) * 2007-10-18 2009-04-23 Allergan, Inc. Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists
US20100203165A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
US8283350B2 (en) * 2008-08-01 2012-10-09 Alpha Synergy Development, Inc. Compositions and methods for reducing capillary permeability
FR2942138A1 (fr) * 2009-02-16 2010-08-20 Galderma Res & Dev Association de composes pour le traitement ou la prevention des affections dermatologiques
KR20120125230A (ko) * 2009-10-26 2012-11-14 갈더마파마 에스.아. 급성 홍반 치료 또는 예방 방법
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
BR112012024289A2 (pt) * 2010-03-26 2017-07-18 Galderma Res & Dev "método para fornecer um tratamento seguro e efetivo do eritema e composição de gel tópica"
RU2535008C2 (ru) * 2010-03-26 2014-12-10 Галдерма Ресерч Энд Девелопмент Улучшенные способы и композиции для безопасного и эффективного лечения телеангиэктазии
CA2810267A1 (en) * 2010-08-06 2012-02-09 Galderma Research & Development Combination of compounds for treating or preventing skin diseases

Also Published As

Publication number Publication date
CN104136029A (zh) 2014-11-05
TW202014189A (zh) 2020-04-16
MY182553A (en) 2021-01-25
EP3763370A1 (en) 2021-01-13
ES2635421T3 (es) 2017-10-03
IL268757A (en) 2019-10-31
JP2014533271A (ja) 2014-12-11
IL232483A0 (en) 2014-06-30
RU2630978C2 (ru) 2017-09-15
US9308201B2 (en) 2016-04-12
ZA201403396B (en) 2015-07-29
SG11201402246RA (en) 2014-06-27
JP6526737B2 (ja) 2019-06-05
EP3184110A1 (en) 2017-06-28
IL261269A (en) 2018-10-31
EP2776034B1 (en) 2017-03-22
AU2016216627A1 (en) 2016-09-08
BR112014011336A2 (pt) 2017-05-02
MX350662B (es) 2017-09-13
EP2776034A1 (en) 2014-09-17
JP6359456B2 (ja) 2018-07-18
RU2667645C1 (ru) 2018-09-21
UA109359C2 (xx) 2015-08-10
US20150231128A1 (en) 2015-08-20
JP2017149767A (ja) 2017-08-31
AU2012335803B2 (en) 2016-05-26
PH12014501051A1 (en) 2022-11-02
SG10201609145PA (en) 2016-12-29
AU2016216627B2 (en) 2017-10-19
CA2855005A1 (en) 2013-05-16
AU2012335803A1 (en) 2014-05-29
TW201713338A (zh) 2017-04-16
TWI580424B (zh) 2017-05-01
TW201328694A (zh) 2013-07-16
CA2855005C (en) 2016-11-22
NZ624771A (en) 2016-11-25
EP3184110B1 (en) 2020-10-07
IL232483B (en) 2018-10-31
WO2013070861A1 (en) 2013-05-16
US20160051534A1 (en) 2016-02-25
MX2014005640A (es) 2014-09-22
AR088845A1 (es) 2014-07-10
US20170095466A1 (en) 2017-04-06
DK2776034T3 (en) 2017-07-10
SG10201809506TA (en) 2018-11-29
RU2014122758A (ru) 2015-12-20
KR102004563B1 (ko) 2019-07-26
CL2014001242A1 (es) 2014-11-14
US20130123303A1 (en) 2013-05-16
KR20140107237A (ko) 2014-09-04

Similar Documents

Publication Publication Date Title
TWI708604B (zh) 用於治療皮膚疾病及病狀之包含7-(1h-咪唑-4-基甲基)-5,6,7,8-四氫-喹啉之醫藥組合物
US10201535B2 (en) Pharmaceutical compositions comprising 7-(1H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
JP2014521644A (ja) 皮膚疾患の治療のための４−ブロモ−ｎ−（イミダゾリジン−２−イリデン）−１ｈ−ベンズイミダゾール−５−アミンを含む薬学的組成物
NZ624771B2 (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees